---
title: 'Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory
  Follicular Lymphoma: ELARA Trial Update'
date: '2024-01-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38194692/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240110170437&v=2.18.0
source: Blood
description: 'Tisagenlecleucel is approved for adults with relapsed/refractory (r/r)
  follicular lymphoma (FL) in the ≥3rd-line setting. The primary analysis (median
  follow-up: 17 months) of the Phase II ELARA trial (ClinicalTrials.gov identifier:
  NCT03568461) reported high response rates and excellent safety profile in extensively
  pretreated patients with r/r FL. Here we report longer-term efficacy, safety, pharmacokinetic,
  and exploratory biomarker analyses after a median follow-up of 29 months. As of
  ...'
disable_comments: true
---
Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the ≥3rd-line setting. The primary analysis (median follow-up: 17 months) of the Phase II ELARA trial (ClinicalTrials.gov identifier: NCT03568461) reported high response rates and excellent safety profile in extensively pretreated patients with r/r FL. Here we report longer-term efficacy, safety, pharmacokinetic, and exploratory biomarker analyses after a median follow-up of 29 months. As of ...